* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Jason Mehar
SVP, Investments & Deputy General Counsel
New York, New York
05 Aug 2025
On May 16, 2025, Royalty Pharma Holdings Ltd ("RPH"), a subsidiary of Royalty Pharma plc, consummated the previously announced internalization transaction by and among RPH, Royalty Pharma Manager, LLC and RP Management, LLC. RP Management, LLC and Pablo G. Legorreta no longer have discretion over the previously reported positions and this will be their final filing.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.